Premium
Blinatumomab as a bridge to further therapy in cases of overwhelming toxicity in pediatric B‐cell precursor acute lymphoblastic leukemia: Report from the Israeli Study Group of Childhood Leukemia
Author(s) -
Elitzur Sarah,
AradCohen Nira,
BarzilaiBirenboim Shlomit,
BenHarush Miriam,
Bielorai Bella,
Elhasid Ronit,
Feuerstein Tamar,
Gilad Gil,
Gural Alexander,
Kharit Mira,
Litichever Naomi,
Nirel Ronit,
Weinreb Sigal,
Wolach Ofir,
Toren Amos,
Izraeli Shai,
Jacoby Elad
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27898
Subject(s) - blinatumomab , medicine , toxicity , chemotherapy , leukemia , oncology , refractory (planetary science) , lymphoblastic leukemia , salvage therapy , acute lymphocytic leukemia , physics , astrobiology
Tremendous progress in the therapy of pediatric acute lymphoblastic leukemia (ALL) has been achieved through combination cytotoxic chemotherapy, leading to high cure rates, at the cost of significant life‐threatening toxicity. The bispecific T‐cell engager blinatumomab, recently approved for relapsed/refractory ALL, has a unique nonmyelotoxic toxicity profile. As blinatumomab causes B‐cell depletion, the safety of its use during severe chemotherapy‐induced toxicity is unclear. We report 11 pediatric patients with ALL, treated with blinatumomab following overwhelming chemotherapy‐associated toxicity, with recovery of all patients and successful bridging to further antileukemia therapy. Blinatumomab can be considered for rare patients who cannot tolerate cytotoxic therapy.